Immunologic adjuvants can stimulate DC maturation, enhancing the expression of MHC-II, CD40, and CD86, thereby improving the generation of tumor-specific CD8+ T cells and promoting tumor suppression [68]. The gene discussed is CD8A; the disease is neoplasm.